Dry Eye

Aramis Biosciences announces FDA clearance of IND application for A197

According to the company, A197 is a novel, first-in-class, topical immunomodulatory agent which will move into Phase II clinical trials in dry eye patients.

Okyo Pharma announces its drug candidate OK-101 demonstrates potential for treating dry eye disease

According to the company, OK-101 displays both anti-inflammatory and ocular pain-reducing potential.

Rethinking dry eye disease with acute steroid treatment

According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation

Oyster Point Pharma reports FDA approval of TYRVAYA nasal spray for DED treatment

October 18, 2021

Oyster Point Pharma, Inc. announced Monday that the U.S. FDA has granted approval of its TYRVAYA (varenicline solution) nasal spray 0.03 mg for the treatment of dry eye disease (DED), making it the first — and only — nasal spray approved for DED treatment in the U.S